A Single-Arm, Open-Label, Phase II Clinical Study to Evaluate the Efficacy and Safety of SHR-1918 in Patients With Homozygous Familial Hypercholesterolemia

This clinical study focuses on testing a drug called SHR-1918 to see how effective it is in lowering "bad" cholesterol, also known as low-density lipoprotein cholesterol (LDL-C), in people who have homozygous familial hypercholesterolemia (HoFH). HoFH is a rare genetic condition where individuals inherit a tendency for high cholesterol levels from both parents, which can lead to serious heart problems. This study is important because it aims to find a better treatment for lowering LDL-C in these patients, potentially reducing their risk of heart disease and improving their quality of life. In this study, participants with HoFH will receive the drug SHR-1918. The study is open-label, meaning both the researchers and participants will know they are receiving this specific treatment, and it is single-arm, meaning all participants receive the same treatment without a comparison group. The main focus is to measure how much the levels of LDL-C decrease, helping researchers understand the drug's effectiveness. While the study does not list specific risks or benefits, participants will be closely monitored to ensure their safety and to observe the drug's effects.